NAION is the second most frequent cause of vision loss due to optic nerve damage, with advanced age and long-standing type 2 ...

Biotechs investigate mitochondria-targeting drugs to claim a share in the weight loss drug market dominated by GLP-1RAs.

As rates of childhood obesity rise, clinicians call for increased data collection to support insurance coverage and safe use of glucagon-like peptide 1 (GLP-1) medications in children under 12 years.

Weight-inclusive health care is the provision of equitable care without perpetuating weight stigma among patients of all body shapes and sizes.

Conshohocken, Pa. Friday, August 1, 2025, 15:00 Hrs [IST] ...

In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...

Long Islanders suffering from sleep apnea inundated the sleep center at St. Charles Hospital in Port Jefferson with phone ...

Conference call begins at 4:30 p.m. Eastern time todayMIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six ...

Research increasingly suggests that nutrient sequencing—eating macronutrients like protein and fiber in a particular ...

Fiber, admittedly, isn’t the sexiest macro—it’s best known for helping you go to the bathroom—but it is super important. Over ...

Topline results from the SURPASS-CVOT trial show that once-weekly tirzepatide has a cardiovascular risk profile similar to ...